U.S. Application No.: 10/662,441 Attorney Docket No. 063779-5001-US

## LISTING OF CLAIMS:

This listing of claims provided below will replace all prior versions and listings of claims in the application. Please amend the claims as follows:

Claims 1-56. (Canceled).

57. (Currently Amended) A method for achieving therapeutically beneficial levels of a drug in a cell, which comprises administering to a patient in need thereof a therapeutically effective amount of an anticancer drug having a covalent bond to a lipophilic moiety, wherein said lipophilic moiety is a cis- or trans-n-9 monounsaturated fatty acid, fatty acid alcohol or fatty amine having a chain length of 18 or 20 carbon atoms, wherein the anticancer drug is megestrol, medroxyprogesterone, hexestrol, trilostane, amino-glutethimide, epitiostanol, calusterone, podophyllinic acid 2-ethylhydrazide, taxol, mopidamol, mitoxantrone, lonidamine, etoposide, eflornitine, defosamide, trimetrexate, methotrexate, deopterin, thioguanin, thiamiprene, mercaptopurin, dacarbazine, nimustine, chlorozotocin, melphalan, estramustin, cyclophosphamide, chlorambucil, or trimethyolmelamine.

58-69. (Canceled)

- (Currently Amended) The method of claim 60 claim 57, wherein the lipophilic moiety has 18 carbon atoms.
- (Currently Amended) The method of elaim 56 claim 57, wherein the patient is a human.

72-76. (Canceled).

77. (Original) The method of claim 57, wherein the anticancer drug is taxol.

U.S. Application No.: 10/662,441 Attorney Docket No. 063779-5001-US

78-87. (Canceled).

 (Currently Amended) The method of elaim 58 claim 57, wherein the lipophilic moiety has 20 carbons 18-earbon atoms.

89-119. (Canceled).